Transgenomic, Rubicon Genomics | GenomeWeb

Transgenomic, Rubicon Genomics

Premium

Transgenomic Plans Diagnostics Debut Without Opening Its Wallet

Despite having laid off a quarter of its staff, including its CFO, earlier this month, Transgenomic said it is still driving to make its Wave platform a player in the diagnostics arena.

However, don’t expect the company to spend additional cash to get itself there.

“We are optimistic about emerging opportunities to leverage our Wave technology in several higher-value markets, including molecular diagnostics and oncology-related theranostics,” said CEO Collin D’Silva.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.